Collegium Pharmaceutical Reports Third-Quarter Revenue of $216.34 Million
Collegium Pharmaceutical’s product revenues rose as higher Jornay PM sales and the addition of Azstarys more than offset declines in Nucynta, Xtampza ER, Belbuca and Symproic. Net income fell amid higher selling, general and administrative expenses, including acquisition costs.
Collegium Pharmaceutical’s third-quarter product revenues rose as higher Jornay PM sales and the addition of Azstarys more than offset declines in Nucynta, Xtampza ER, Belbuca and Symproic. Net income fell, as higher selling, general and administrative expenses—including acquisition costs and a lit…